MariMed Inc. Files Proxy to Approve Reverse Stock Split

What Happened

• On September 23, 2026, MariMed Inc. announced via press release (Exhibit 99.1) that it has filed a definitive proxy statement (Schedule 14A) with the SEC in connection with a special meeting to seek stockholder approval of a reverse stock split (the “Reverse Stock Split Proposal”). The proxy statement was filed on September 22, 2026.

Key Details

• The company issued the press release on September 23, 2026 and filed the definitive proxy on Schedule 14A with the SEC on September 22, 2026.
• The vote will be held at a special meeting of stockholders; materials will be made available to holders of record as of the meeting’s record date.
• MariMed disclosed that its directors and executive officers may be participants in the solicitation of proxies.
• The release includes forward-looking statements about the potential listing of the company’s common stock on a national exchange and the anticipated effects of the reverse split, with standard risk disclosures.

Why It Matters

• A reverse stock split, if approved, would consolidate shares and change the per-share price and share count, which can affect liquidity, listing eligibility, and investor perception. The proxy filing starts the formal process and gives stockholders the information needed to vote. Investors should read the definitive proxy and related SEC filings (available at www.sec.gov and www.marimedinc.com) before making any decision.